Recently announced topline findings from the phase 2 SEQUEL study (NCT04735536) highlight the positive impact of CT1812, an investigational agent, on brain function in patients with mild to moderate Alzheimer’s disease (AD). The study, supported by a grant from the National Institute on Aging, involved 16 individuals and assessed differences in synaptic function using quantitative electroencephalogram (qEEG). While not statistically significant, CT1812 demonstrated a numerical reduction in relative theta power, indicating a positive impact on underlying brain function. Treatment with CT1812 also resulted in decreases in relative theta in frontal, central, temporal, and posterior regions, with statistically significant changes observed in the central region. The principal investigator expressed excitement over these results, suggesting that CT1812 may directly impact overall brain health. Full analyses of the study’s results, including AD biomarkers and proteomics, will be presented at an upcoming medical meeting. Additionally, CT1812 is being further studied in the SHINE study, a six-month treatment period involving 144 adults with mild-to-moderate Alzheimer’s disease. CT1812 is an experimental small molecule designed to penetrate the blood-brain barrier and selectively bind to the sigma-2 receptor complex. This promising development offers hope for improved Alzheimer’s treatments and underscores the growing body of evidence supporting CT1812’s efficacy.

To know more: About the original article click here.